Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Feb;71(2):363–365. doi: 10.1038/bjc.1995.73

Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).

M Schlumberger 1, N Abdelmoumene 1, M J Delisle 1, J E Couette 1
PMCID: PMC2033569  PMID: 7530987

Abstract

Combinations of 5-fluorouracil (5-FU) and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 11 long-term stabilizations were observed. No unexpected toxicity occurred.

Full text

PDF
363

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Droz J. P., Schlumberger M., Rougier P., Ghosn M., Gardet P., Parmentier C. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori. 1990 Oct 31;76(5):480–483. doi: 10.1177/030089169007600513. [DOI] [PubMed] [Google Scholar]
  2. Hoskin P. J., Harmer C. Chemotherapy for thyroid cancer. Radiother Oncol. 1987 Nov;10(3):187–194. doi: 10.1016/s0167-8140(87)80004-x. [DOI] [PubMed] [Google Scholar]
  3. Husain M., Alsever R. N., Lock J. P., George W. F., Katz F. H. Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy. Horm Res. 1978;9(1):22–25. doi: 10.1159/000178893. [DOI] [PubMed] [Google Scholar]
  4. Kessinger A., Foley J. F., Lemon H. M. Therapy of malignant APUD cell tumors. Effectiveness of DTIC. Cancer. 1983 Mar 1;51(5):790–794. doi: 10.1002/1097-0142(19830301)51:5<790::aid-cncr2820510507>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  5. Mahler C., Verhelst J., de Longueville M., Harris A. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf) 1990 Aug;33(2):261–269. doi: 10.1111/j.1365-2265.1990.tb00490.x. [DOI] [PubMed] [Google Scholar]
  6. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  7. Petursson S. R. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer. 1988 Nov 1;62(9):1899–1903. doi: 10.1002/1097-0142(19881101)62:9<1899::aid-cncr2820620905>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  8. Shimaoka K., Schoenfeld D. A., DeWys W. D., Creech R. H., DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985 Nov 1;56(9):2155–2160. doi: 10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  9. Sridhar K. S., Holland J. F., Brown J. C., Cohen J. M., Ohnuma T. Doxorubicin plus cisplatin in the treatment of apudomas. Cancer. 1985 Jun 1;55(11):2634–2637. doi: 10.1002/1097-0142(19850601)55:11<2634::aid-cncr2820551117>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  10. Williams S. D., Birch R., Einhorn L. H. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986 Mar;70(3):405–407. [PubMed] [Google Scholar]
  11. Wu L. T., Averbuch S. D., Ball D. W., de Bustros A., Baylin S. B., McGuire W. P., 3rd Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer. 1994 Jan 15;73(2):432–436. doi: 10.1002/1097-0142(19940115)73:2<432::aid-cncr2820730231>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES